

Andre van der Westhuizen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3784865/publications.pdf>

Version: 2024-02-01

10
papers

258
citations

1307366

7
h-index

1588896

8
g-index

10
all docs

10
docs citations

10
times ranked

598
citing authors

#	ARTICLE	IF	CITATIONS
1	Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 127-138.	5.1	91
2	Metastatic melanoma treatment: Combining old and new therapies. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 98, 242-253.	2.0	64
3	The McCaVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC). <i>Oncologist</i> , 2020, 25, e451-e459.	1.9	30
4	Monitoring Patient Response to Pembrolizumab With Peripheral Blood Exhaustion Marker Profiles. <i>Frontiers in Medicine</i> , 2019, 6, 113.	1.2	25
5	Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 347-359.	1.1	19
6	Sequential decitabine and carboplatin treatment increases the DNA repair protein XPC, increases apoptosis and decreases proliferation in melanoma. <i>BMC Cancer</i> , 2018, 18, 100.	1.1	14
7	Immune checkpoint blockade in solid organ tumours: Choice, dose and predictors of response. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1736-1752.	1.1	10
8	How anti-PD1 treatments are changing the management of melanoma. <i>Melanoma Management</i> , 2014, 1, 165-172.	0.1	5
9	Abstract 4811: Global demethylation with decitabine increases DNA repair and sensitizes melanoma to carboplatin. , 2016, , .		0
10	Borderline resectable pancreas adenocarcinoma managed with neoadjuvant chemoradiotherapy: A prospective case series.. <i>Journal of Clinical Oncology</i> , 2017, 35, 499-499.	0.8	0